BioVaxys Technology Corp CEO James Passen tells Proactive it has broadened its intellectual property portfolio, after filing an international application for CoviDTH — its T cell diagnostic for detecting an immune response to SARS-CoV-2 — with the Patent Cooperation Treaty.
Passen says because of the urgent importance of commercializing a low-cost diagnostic for T cell immunity to Covid-19 in the context of the global pandemic, it is protecting intellectual property in key international markets as it continues to advance towards the submission of an IND in the US.